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1251cularization and Stents in Acute Myocardial Infarction] trial) (4),
and, hopefully, this number will further decrease with the increas-
ing emphasis on pan-arterial revascularization.
We agree that, given its infrequent occurrence, it will be difficult
to accrue meaningful data on best treatments for STEMI from
adequately powered randomized trials. Absent such data, we
empirically recommend potent antiplatelet and antithrombotic
agents (in patients at low risk of bleeding) and liberal use of
intragraft vasodilators to prevent and treat no-reflow. Either
proximal or distal embolic protection devices should also routinely
be used, with consideration of aspiration or thrombectomy for
further debulking. Drug-eluting stents have now been shown to be
safe in SVGs and might decrease restenosis (5). Preferential
intervention of the native coronary arterial circulation (rather than
the occluded SVG) should always be considered as an alternative
route to reperfusing the myocardium and, if possible, will result in
higher acute success and late patency rates (6).
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We have read with great interest the paper from Brilakis et al. (1)
concerning percutaneous coronary interventions (PCI) following
coronary artery bypass graft (CABG). Patients with a previous
CABG constitute an extremely high-risk group with an increased
frequency of comorbidities and multivessel disease. Brilakis et al.
notice very well that patients undergoing bypass graft PCI have
higher-risk clinical characteristics. Our attention was especially
attracted to the very important and didactic conclusion that
compared with native coronary PCI, bypass graft PCI is indepen-
dently associated with higher in-hospital mortality, which relates
to our research that soon will be published by Xanthopoulou et al.
(2). Interestingly, the 2 papers supplement each other, as at this
retrospective analysis of 190 patients, we found that post-CABG
patients, undergoing graft compared with native vessel PCI have
worse long-term clinical outcome (follow-up with a median
duration of 28 months) in terms of major adverse cardiac events,
death, and repeat revascularization. Brilakis et al. also found that
saphenous vein graft PCI becomes more prevalent with longer
time intervals from CABG, a finding in accordance with our
results.
By contrast, although the efficacy of embolic protection devices
is proven, the investigators do not mention the frequency of their
use in the saphenous vein graft PCI population (3). Additionally,
it would be important to assess the amount of myocardium in
jeopardy following PCI in the 2 groups. According to our opinion,
it would be helpful to incorporate those parameters in the
multivariate analysis, as they could have influenced the clinical
outcome of those patients (4).
Disease progression to the native vessels (NV) or failure of
grafts due to similar mechanisms with NV atherosclerosis usually
lead to repeat coronary revascularizations (5). Furthermore, the
NV is recommended as the ideal target for PCI when diseased
grafts are 3 years old (6).
In conclusion, it is clear that regardless of the selection criteria
for the PCI target vessel, patients subjected to graft PCI have
worse in-hospital mortality than patients who had NV-PCI, and
these data could be enhanced with our results adding details about
long-term clinical outcome. Physicians should prefer a NV if PCI
is to be performed in a patient following CABG, if the anatomy of
the vessels of the heart is suitable for it.
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Reply
We greatly appreciate the interest in our paper (1) and the astute
comments by Drs. Tsigkas, Xanthopoulou, and Alexopoulos who
highlight the use of embolic protection devices (EPDs) in saphe-
nous vein graft (SVG) percutaneous coronary interventions (PCI)
and the importance of the amount of myocardium in jeopardy.
While we agree that the amount of jeopardized myocardium is an
important predictor of outcome, the information necessary to
calculate the amount of myocardium in jeopardy during PCI is not
available in the CathPCI Registry. EPDs were used in 19.64% of
SVG PCIs during the study period. EPD use was not associated
with in-hospital mortality in univariable analysis (odds ratio:
0.988, 95% confidence interval: 0.870 to 1.122) or multivariable
analysis (odds ratio: 0.935, 95% confidence interval: 0.813 to
1.075). Longer-term follow-up is likely needed to detect an impact
from EPD use on clinical outcomes.
EPDs have been proved to reduce the incidence of post-SVG
PCI myocardial infarction, and have a Class I indication in the
American College of Cardiology/American Heart Association
PCI guidelines. Yet, EPDs remain underutilized both in the
United States and in Europe (2), due to device complexity,
difficulties assessing the embolization risk of each SVG lesion,
unavailability of a universally applicable EPD, and lack of reim-
bursement (3,4).
The similarity of the findings from the population of Xantho-
poulou et al. (5) and from NCDR (1) strengthen the conclusionthat native coronary artery PCI is preferable to SVG PCI in prior
coronary artery bypass graft patients, if technically feasible. Given
the rapid advances in complex PCI techniques, especially chronic
total occlusion PCI (6,7), native coronary artery interventions are
likely to be increasingly utilized in the future in patients presenting
with SVG failure.
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